北京大学第三医院

血管稳态与重构全国重点实验室

xhua@bjmu.edu.cn

花欣炜，博士，北京大学第三医院研究员，博士生导师, 血管稳态与重构全国重点实验PI。先后分别于美国埃默里大学、美国华盛顿大学获流行病学硕士与博士学位，并于哈佛大学医学院/麻省总医院完成博士后研究。于2022年回国就职于北京大学第三医院心血管内科，先后入选国家级海外高层次人才计划青年项目、北京市科技新星，主持国自然、北京市自然重点专题项目子课题等纵向科研项目。主要研究方向包括利用多组学技术和分子流行病学方法探究外环境因子与分子表征及其交互作用在心血管疾病发生和发展中的作用、利用多维度健康大数据（多维度临床数据、多组学数据、以及影像学数据）和人工智能方法辅助心血管疾病的早期诊断和精准治疗。至今以第一作者或者通讯作者（含共同）在J Clinical Oncology、Gastroenterology、Clinical Gastroenterology and Hepatology、Int J Cancer等国际知名学术期刊上发表论文20余篇。

教育经历:

2016-2020 博士学位，美国华盛顿大学，流行病

2010-2012 公共卫生硕士，美国埃默里大学，流行病

2006-2010 工科学士，华南理工大学，生物工程

科研工作经历：

2022/04至今 研究员，北京大学第三医院

2020/10 -2021/12 博士后，美国麻省总医院/哈佛大学医学院

2014/09 -2020/10 助理研究员, 美国华盛顿大学/ Fred Hutchinson Cancer Research Center

研究方向

o 搭建心血管疾病的专病前瞻性队列（心血管代谢、心力衰竭等）以及大规模生物样本库，整合电子病历数据（EMR）与分子表征用于开发射血分数保留心衰患者的诊断、分型和风险评估工具，以指导个体化干预。

o 研究心血管疾病的环境因素（如生物标志物，生活方式）、遗传因素及其交互作用对心血管疾病患病风险的影响。

o 利用多组学，如代谢组学、蛋白组、肠道微生物组，探讨心血管代谢性疾病的发病机制，寻找新的生物靶点和干预途径，结合多维度临床数据、以及医学影像资料，利用人工智能方法辅助心血管疾病的早期鉴别诊断和精准治疗。

Xinwei Hua, PhD, MPH

Investigator/Assistant Professor of Epidemiology

Department of Cardiology

Peking University Third Hospital

Peking University Health Science Center

National Key Laboratory of Vascular and Reconstructive Diseases

xhua@bjmu.edu.cn

Dr. Xinwei Hua, a molecular and cardiovascular epidemiologist, focuses on studying the molecular and clinical epidemiology of cardiometabolic diseases. By integrating electronic medical record (EMR) data with molecular profiles, her research involves the identification of novel therapeutical and gut-microbial targets for cardiometabolic disease prevention and treatment, and the development of diagnostic, phenotyping and risk assessment tools for individualized treatment for patients with heart failure with preserved ejection fraction.

Education

PhD, Epidemiology, University of Washington, 2016-2020

MPH, Epidemiology, Emory University, 2010-2012

BE, Bioengineering, South China University of Technology, 2006-2010

Research Experiences

2022/04 to Current Assistant professor, Peking University Third Hospital

2020/10 -2021/12 Postdoctoral research fellow, Mass General Hospital/ Havard Medical School

2014/09 -2020/10 Research associate, Fred Hutchinson Cancer Research Center

Research interests

o Drug, gut microbiome and cardiometabolic disease (CMD)

o Molecular profiling, phenotyping of heart failure with preserved ejection fraction

o Diagnostic, phenotyping and risk assessment tools for CMD

Publications

1. Hua X#*, Ungaro RC#*, Petrick LM, Chan AT, Porter CK, Khalili H (2023), Inflammatory Bowel Disease is Associated with Prediagnostic Perturbances in Metabolic Pathways, Gastroenterology, 164.1: 147-150. [IF=29.4, JCR Q1]

2. Zhou Q, Yang J, Wang W, Shao C, Hua X*, Tang YD* (2023). The Impact of the Stress Hyperglycemia Ratio on Mortality and Rehospitalization Rate in Patients with Acute Decompensated Heart Failure and Diabetes. Cardiovascular Diabetology 22 (1): 189. [IF: 9.3, JCR Q1]

3. Zhou Q, Yang J, Tang H, Guo Z, Dong W, Wang Y, Meng X, Zhang K, Wang W, Shao C. and Hua X*, Tang YD* (2023). High triglyceride-glucose (TyG) index is associated with poor prognosis of heart failure with preserved ejection fraction. Cardiovascular Diabetology, 22(1): 263. [IF: 9.3, JCR Q1]

4. Fuller H, Zhu Y, Nicholas J, Chatelaine HA, Drzymalla EM, Sarvestani AK, Julián-Serrano S, Tahir UA, Sinnott-Armstrong N, Raffield LM, Rahnavard A, Hua X, Shutta KH, Darst BF (2023). Metabolomic Epidemiology Offers Insights into Disease Aetiology. Nature Metabolism 5 (10): 1656–72. (IF=20.8, JCR Q1)

5. Joshi AD, Rahnavard A, Kachroo P, Mendez KM, Lawrence W, Julián-Serrano S, Hua X, Fuller H, Sinnott-Armstrong N, Tabung FK, Shutta KH, Raffield LM, Darst BF, COMETS Early Career Scientist Working Group. (2023). An Epidemiological Introduction to Human Metabolomic Investigations. Trends in Endocrinology and Metabolism: TEM 34 (9): 505–25. [IF=10.9, JCR Q1]

6. Hua X, Lopes EW, Burke KE, Ananthakrishnan A, Rtchter J, Lo CH, Lochhead P, Chan AT, Khalili H (2022), Smoking behavior changes after diagnosis of inflammatory bowel disease and risk of all-cause mortality, Journal of Crohn’s and Colitis, 16(7):1030-1038. [IF: 10.02, JCR Q1]

7. Hua X#, Cao Y#, Morgan DM, Miller K, Chin SM, Bellavance D, Khalili H (2022), Longitudinal analysis of the impact of oral contraceptive use on the gut microbiome, Journal of Medical Microbiology, 71(4), 001512. [IF: 3.196, JCR Q4]

8. Huang Y, Hua X*, Labadie JD, Harrison TA, Dai J, Lindstrom S, Lin Y, Berndt SI, Buchanan DD, Campbell PT, Casey G, Gallinger SJ, Gunter MJ, Hoffmeister M, Jenkins MA, Sakoda LC, Schoen RE, Diergaarde B, Slattery MI, White E, Giles GG, Brenner H, Chang-Claude J, Joshi AD, Ma W, Pai RK, Chan AT, Peters U, Newcomb PA* (2022). Genetic variants associated with circulating C-reactive protein levels and colorectal cancer survival: Sex- and lifestyle factors- specific associations, International Journal of Cancer, 150(9):1447-1454. [IF: 7.316, JCR Q1]

9. Hua X, Kratz M, Malen R, Dai J, Lindstroem S, Zheng Y, Newcomb PA (2021). Associations between post-treatment inflammatory biomarkers and survival among stage II-III colorectal cancer patients, British Journal of Cancer, 125, 806–815. [IF: 9.075, , JCR Q1]

10. Hua X, Dai J, Lindstrom S, Harrison TA, Lin Y, Alberts SR, Alwers E, Berndt SI, Brenner H, Buchanan DD, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Giles GG, Goldberg RM, Gunter MJ, Hoffmeister M, Jenkins MA, Joshi AD, Ma W, Milne RL, Murphy N, Pai RK, Sakoda LC, Schoen RE, Shi Q, Slattery MI, Song M, White E, Le Marchand L, Chan AT, Peters U, Newcomb PA (2021). Genetically predicted circulating C-reactive protein and colorectal cancer survival: A Mendelian randomization study, Cancer Epidemiology, Biomarkers, and Prevention, 30 (7): 1349–1358. [IF: 4.09, JCR Q2]

11. Hua X, Newcomb PA, Chubak J, Malen RC, Ziebell R, Kamineni A, Zhu LC, Upton MP, Wurscher MA, Thomas SS, Newman H, Hardikar S, Burnett-Hartman AN (2020). Colorectal serrated polyp molecular characteristics associated with subsequent advanced colorectal neoplasia. Cancer Causes and Control, 31(7):631-640. [IF: 2.53, JCR Q2]

12. Zheng Y, Hua X, Win AK, MacInnis RJ, Gallinger S, Marchand LL, Lindor NM, Baron JA, Hopper JL, Dowty JG, Antoniou AC, Jenkins MA, Newcomb PA (2020). A new comprehensive colorectal cancer risk prediction model incorporating personal characteristics, family history, and environmental factors. Cancer Epidemiology, Biomarkers, and Prevention, 29(3), 549-557. [IF: 4.09, JCR Q2]

13. Penney KL, Banbury BL, Bien S, Harrison TA, Hua X, Phipps AI, Sun W, Song M, Joshi AD, Alberts SR, Allegra CJ, Atkins J, Colangelo LH, George TJ, Goldberg RM, Lucas PC, Nair SG, Shi Q, Sinicrope FA, Wolmark N, Yothers G, Peters U, Newcomb PA, Chan AT (2020). Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer. Clinical Gastroenterology and Hepatology. 18(12):2717-2723.e3. [IF: 13.576, JCR Q1]

14. Hua X, Phipps AI, Burnett-Hartman AN, Adams SV, Hardikar S, Cohen SA, Kocarnik JM, Ahnen DJ, Lindor NM, Baron JA, and Newcomb PA (2017), Timing of aspirin and other nonsteroidal anti-inflammatory drug use among patients with colorectal cancer in relation to tumor markers and survival, Journal of Clinical Oncology, 35, 2806-2813. [IF: 50.717, JCR Q1]

15. Kocarnik JM, Hua X, Hardikar S, Robinson J, Lindor NM, Win AK, Hopper JL, Figueiredo JC, Potter JD, Campbell PT, Gallinger S, Cotterchio M, Adams SV, Cohen SA, Phipps AI and Newcomb PA (2017). Long-term weight loss after colorectal cancer diagnoses is associated with lower survival: The Colon Cancer Family Registry, Cancer, 123(23): 4701-4708. [IF: 6.92, JCR Q1]

16. Hua X, Ward, KC, Gillespie, TW, Lipscomb J, Goodman M (2014). Non-small cell lung cancer treatment receipt and survival among African Americans and whites in a rural area, Journal of Community Health, 39(4), 696-705. [IF: 4.371, JCR Q2]